Evidence Hub

Silent Invader—Unrevealing Lethal Encounter with Pulmonary Mucormycosis: A Rare Case Report

Vijay Kumar, B. Gowthami, Mohit Bhatia, Venkat Raj, D. Shah, M. Gupta, Subham Sahoo, Murli D. Saini et al.

Indian Journal of Respiratory Care, 2024

Abstract

REPORTwas 7, and four minor criteria were positive in severe communityacquired pneumonia (CAP) score.Hence, the patient was shifted to high dependency unit (HDU) and started with intravenous (IV)-antibiotics-meropenem (1 gm 8th hourly), linezolid (600 mg 12th hourly), moxifloxacin (400 mg 24th hourly), and voriconazole (200 mg BD).His serum procalcitonin (PCT) was raised at 0.75 ng/mL, and D-dimer was 1250 ng/mL.Two-dimensional echocardiography (2D-ECHO) and bilateral lower limb color Doppler were done to rule out vascular thrombosis, which came out to be normal.On the 2nd day of admission, the patient's counts were still in the higher range.On direct microscopic examination of early morning sputum, broad aseptate hyphae having right-angle branching, morphologically resembling to Mucorales, were observed in

How strong is the evidence?

Evidence Hub reads this as a case report, done in people. Its evidence level is 5 of 5 (Very low · case / narrative / animal / in vitro / in silico). Case reports, narrative reviews, and animal, cell or computer-model studies give the weakest evidence for human health.

How the five levels of evidence work. The level is assigned automatically from the abstract and can be wrong, so check the paper.

Read the paper

Related studies

Go deeper in Evidence Hub

Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.

Open this study Sign up free